IRP’s Stephen Chanock Elected to National Academy of Medicine
IRP senior investigator Stephen J. Chanock, M.D., grew up on the NIH campus, spending many weekends hanging around his father’s lab. Robert M. Chanock, M.D., worked at NIH for 50 years, during which he identified the human respiratory syncytial virus and was elected to the National Academy of Medicine (NAM) for his discoveries. Now, following in his dad’s footsteps, the younger Dr. Chanock has been elected to the NAM for his contributions to our understanding of how inherited genetic variation and environmental factors contribute to the risk of developing cancer.
IRP Research Could Lead to Light-Activated Treatments for Numerous Diseases
Many helpful contraptions we use every day would be problematic if we couldn’t turn them off when we didn't need them. After all, you wouldn’t want to leave your oven on when you’re out of town, and most people wouldn’t sleep well with their bedside lamp on all night. Many medical treatments would benefit from the same flexibility, but creating such treatments is no easy task. IRP researchers recently took a significant step forward in this area by creating an experimental treatment for an irritating skin condition that can be activated and inactivated using different colors of light.
IRP’s Clifton Barry Seeks Novel Therapies for an Ancient Foe
March 24 is World Tuberculosis Day, a day to remember that a preventable and curable disease still kills more than a million people each year. Despite every effort to eradicate it, the disease-causing bug, Mycobacterium tuberculosis, keeps coming back stronger and more ready for a fight. As varieties of the bacteria grow more and more resistant to treatment, an evolutionary war is raging between the bacterium and researchers like IRP senior investigator Clifton Barry, Ph.D., who has been seeking solutions for the past 33 years.
IRP’s Paul Hwang Discovers How Muscle Cells Gear Up for Training
As the weather warms up in March, which is National Athletic Training Month, many of us come out of hibernation and finally fulfill that new year’s resolution to start exercising. Deep down in our cells, our mitochondria, the tiny power stations that turn oxygen into energy, start getting a workout, too.
IRP senior investigator Paul Hwang, M.D., Ph.D., studies how mitochondria and cellular energy production affect human health and disease, with a particular focus on cardiovascular health and cancer. However, March’s many new fitness enthusiasts might be most interested in a recent finding from his laboratory that seems to explain how muscles build endurance as we train them through exercise. His team’s insights also explain why muscles revert back to couch potato mode so quickly when we stop regular exercise.
Aspiring Scientists Show off Research Findings at Annual Event
The NIH IRP provides not only a world-class environment for skilled scientists to make groundbreaking discoveries, but also an exhilarating training ground for the next generation of researchers. Among the many budding scientists working on NIH’s campuses are graduate students conducting part of their dissertation research in IRP labs.
Of course, these ambitious trainees aren’t waiting until they receive their degrees to contribute to scientific breakthroughs. At this year’s Graduate Student Research Symposium, more than 100 of them presented research on topics ranging from the skin condition psoriasis to the role of immune cells in Alzheimer’s disease. Read on to learn more about some of the ways current IRP graduate students have expanded our understanding of the human body.
IRP Mouse Study Reveals Factors That Influence Pandemic Virus’ Replication in the Lungs
Tuberculosis, the flu, a staph infection, asthma — you’d think all these ailments could only be bad news for the lungs. However, if they don’t get out of control, they might actually turn out to have an unexpected benefit. A new IRP mouse study suggests that a recent bout with these illnesses might prime the lungs to keep a lid on a COVID-19 infection.
One of the most perplexing aspects of the COVID-19 pandemic was the huge variation in individual experiences with the disease. Despite the incredibly infectious nature of the virus that causes it, SARS-CoV-2, many people never got sick at all, or at least never showed symptoms. For those who showed symptoms, they ranged wildly, mild for some and life-threatening for others.
Rare Disease Day, celebrated on or near February 29 — the rarest day on the calendar — calls attention to the 300 million people in the world who have some sort of rare disease. For children born with one of those diseases, speedy diagnosis and treatment may be necessary to ward off long-term complications, but that’s much easier said than done. This is especially true for pediatric autoinflammatory diseases, in which the immune system attacks the child’s own body. IRP senior investigator Raphaela T. Goldbach-Mansky, M.D., M.H.S., has made it her mission to discover and define these diseases and the genes that cause them, and then find a way to provide treatment.
IRP Research Hints at Potential of Genomic Technologies to Predict Patient Outcomes
Our genes certainly have a huge influence over our risk for disease, but they don’t operate in a vacuum. Rather, they’re decorated with numerous molecular tags like a bejeweled bracelet, and these ‘epigenetic’ markers affect how genes behave. A recent IRP study revealed differences in certain epigenetic markers that may one day help doctors more effectively treat patients with the autoimmune disease known as lupus.
NIH Researcher Explores Why Some Survive Infection-Induced Organ Damage
“When you have eliminated the impossible, whatever remains, however improbable, must be the truth.” That line from Arthur Conan Doyle’s Sherlock Holmes can be applied to mysteries of all sorts, including the ones scientists toil away in their labs to solve. When it comes to solving the many mysteries of sepsis — a life-threatening immune over-reaction to an uncontrolled infection — the process of elimination is leading us closer to answers, thanks to researchers at the NIH Clinical Center.
Sepsis — also known as septic shock in its most severe form — occurs when the body’s immune system kicks into overdrive to fight a severe infection. Unfortunately, rather than just attacking the harmful invaders, the immune system releases chemicals that, when present in excess, cause intense, tissue-damaging inflammation and impair organ function. In recognition of Sepsis Survivors Week, we spoke with IRP Senior Investigator Charles Natanson, M.D., about two of the great mysteries of sepsis: how does sepsis cause organ failure in the first place, and why do some people survive it while so many others die?
Over the last few decades, advances in cervical cancer screening and prevention have fundamentally changed the approach to dealing with one of the most common forms of cancer in younger women. While doctors have been able to detect cancerous and pre-cancerous cells with a Pap smear since the 1940s, the more recent discovery that the human papillomavirus (HPV) causes more than 90 percent of cervical cancers now affords greater accuracy to regular screening tests. What’s more, IRP researchers truly changed the game by developing a vaccine against HPV, which was approved by the U.S. Food and Drug Administration (FDA) in 2006.
Still, despite these extremely positive developments, much work remains to be done, as cervical cancer continues to kill about 4,000 American women each year. In honor of World Cervical Cancer Awareness Month this January, we spoke with IRP Senior Investigator Nicolas Wentzensen, M.D., Ph.D., about his efforts to bring that number as close to zero as possible.
This page was last updated on Friday, January 14, 2022
